 | Meletios‐Athanassios Dimopoulos |
Prominent publications by Meletios‐Athanassios Dimopoulos
BACKGROUND: Panobinostat is a potent oral pan-deacetylase inhibitor that in preclinical studies has synergistic anti-myeloma activity when combined with bortezomib and dexamethasone. We aimed to compare panobinostat, bortezomib, and dexamethasone with placebo, bortezomib, and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma.
METHODS: PANORAMA1 is a multicentre, randomised, placebo-controlled, double-blind phase 3 trial of patients with relapsed or ...
| Also Ranks for: Panobinostat Placebo | dexamethasone patients | multiple myeloma | 3 trial | partial response |
BACKGROUND: The phase 3 ENDEAVOR trial was a head-to-head comparison of two proteasome inhibitors in patients with relapsed or refractory multiple myeloma. Progression-free survival was previously reported to be significantly longer with carfilzomib administered in combination with dexamethasone than with bortezomib and dexamethasone in an interim analysis. The aim of this second interim analysis was to compare overall survival between the two treatment groups.
METHODS: ENDEAVOR was a ...
| Also Ranks for: Bortezomib Carfilzomib | multiple myeloma | 3 trial | interim analysis | previous lines |
BACKGROUND: As lenalidomide becomes increasingly established for upfront treatment of multiple myeloma, patients refractory to this drug represent a population with an unmet need. The combination of pomalidomide, bortezomib, and dexamethasone has shown promising results in phase 1/2 trials of patients with relapsed or refractory multiple myeloma. We aimed to assess the efficacy and safety of this triplet regimen in patients with relapsed or refractory multiple myeloma who previously ...
| Also Ranks for: Dexamethasone Patients | multiple myeloma | pomalidomide bortezomib | phase 3 | received lenalidomide |
BACKGROUND: Isatuximab is a monoclonal antibody that binds a specific epitope on the human CD38 receptor and has antitumour activity via multiple mechanisms of action. In a previous phase 1b study, around 65% of patients with relapsed and refractory multiple myeloma achieved an overall response with a combination of isatuximab with pomalidomide and low-dose dexamethasone. The aim of this study was to determine the progression-free survival benefit of isatuximab plus pomalidomide and ...
| Also Ranks for: 3 Study | pomalidomide dexamethasone | refractory multiple | patients isatuximab | monoclonal antibodies |
BACKGROUND: Bortezomib with dexamethasone is a standard treatment option for relapsed or refractory multiple myeloma. Carfilzomib with dexamethasone has shown promising activity in patients in this disease setting. The aim of this study was to compare the combination of carfilzomib and dexamethasone with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma.
METHODS: In this randomised, phase 3, open-label, multicentre study, patients with relapsed or ...
| Also Ranks for: Bortezomib Dexamethasone | multiple myeloma | patients carfilzomib | primary endpoint | relapsed refractory |
BACKGROUND: Selinexor combined with dexamethasone has shown activity in patients with heavily pre-treated multiple myeloma. In a phase 1b/2 study, the combination of oral selinexor with bortezomib (a proteasome inhibitor) and dexamethasone induced high response rates with low rates of peripheral neuropathy, the main dose-limiting toxicity of bortezomib. We aimed to evaluate the clinical benefit of weekly selinexor, bortezomib, and dexamethasone versus standard bortezomib and ...
| Also Ranks for: Bortezomib Dexamethasone | multiple myeloma | patients selinexor | lines therapy | phase 3 |
BACKGROUND: Standard-of-care treatment for patients with newly diagnosed multiple myeloma includes combination therapies for patients who are not eligible for autologous stem-cell transplantation. At the primary analysis for progression-free survival of the phase 3 ALCYONE trial, progression-free survival was significantly longer with daratumumab in combination with bortezomib, melphalan, and prednisone (D-VMP) versus bortezomib, melphalan, and prednisone (VMP) alone in patients with ...
| Also Ranks for: Vmp Patients | multiple myeloma | bortezomib melphalan | progressionfree survival | phase 3 |
BACKGROUND: Twice a week carfilzomib at 27 mg/m2 is approved for treatment of relapsed or refractory multiple myeloma. Phase 1/2 CHAMPION-1, the first study exploring once-weekly carfilzomib dosing, established the maximum tolerated dose at 70 mg/m2 in combination with dexamethasone. We aimed to compare progression-free survival in patients with relapsed and refractory multiple myeloma given once weekly carfilzomib or twice weekly carfilzomib.
METHODS: In this prespecified interim ...
| Also Ranks for: Weekly Carfilzomib | refractory multiple | 3 study | progressionfree survival | patients relapsed |
BACKGROUND: The emergence of highly active novel agents has led some to question the role of autologous haematopoietic stem-cell transplantation (HSCT) and subsequent consolidation therapy in newly diagnosed multiple myeloma. We therefore compared autologous HSCT with bortezomib-melphalan-prednisone (VMP) as intensification therapy, and bortezomib-lenalidomide-dexamethasone (VRD) consolidation therapy with no consolidation.
METHODS: In this randomised, open-label, phase 3 study we ...
| Also Ranks for: Consolidation Therapy | multiple myeloma | cell transplantation | phase 3 | bortezomib lenalidomide |
BACKGROUND: Few effective treatments exist for patients with refractory or relapsed and refractory multiple myeloma not responding to treatment with bortezomib and lenalidomide. Pomalidomide alone has shown limited efficacy in patients with relapsed multiple myeloma, but synergistic effects have been noted when combined with dexamethasone. We compared the efficacy and safety of pomalidomide plus low-dose dexamethasone with high-dose dexamethasone alone in these patients.
METHODS: This ...
| Also Ranks for: Dose Dexamethasone | refractory multiple myeloma | 3 trial | pomalidomide 4 | previous treatments |
BACKGROUND: Lenalidomide and bortezomib frontline exposure has raised a growing need for novel treatments for patients with relapsed or refractory multiple myeloma. Carfilzomib in combination with daratumumab has shown substantial efficacy with tolerable safety in relapsed or refractory multiple myeloma in a phase 1 study. In this study, we aimed to compare the efficacy and safety of carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone in patients with ...
| Also Ranks for: Carfilzomib Dexamethasone | multiple myeloma | kd patients | 3 study | daratumumab versus |
BACKGROUND: In a phase 1b study, intravenous daratumumab plus pomalidomide and dexamethasone induced a very good partial response or better rate of 42% and was well tolerated in patients with heavily pretreated multiple myeloma. We aimed to evaluate whether daratumumab plus pomalidomide and dexamethasone would improve progression-free survival versus pomalidomide and dexamethasone alone in patients with previously treated multiple myeloma.
METHODS: In this ongoing, open-label, ...
| Also Ranks for: Pomalidomide Dexamethasone | multiple myeloma | patients daratumumab | phase 3 | previous lines |
BACKGROUND: Panobinostat plus bortezomib and dexamethasone significantly increased median progression-free survival compared with placebo plus bortezomib and dexamethasone in the phase 3 PANORAMA 1 trial. Here, we present the final overall survival analysis for this trial.
METHODS: PANORAMA 1 is a randomised, placebo-controlled, double-blind, phase 3 trial of patients with relapsed or relapsed and refractory multiple myeloma with one to three previous treatments. Patients were randomly ...
| Also Ranks for: Bortezomib Dexamethasone | 3 trial | relapsed multiple myeloma | patients panobinostat | treatment phase |
Meletios‐Athanassios Dimopoulos: Influence Statistics
| Concept | World rank |
|---|---|
| extramedullary plasmacytoma diagnosis | #1 |
| ibrutinib zanubrutinib patients | #1 |
| benefit vmp | #1 |
| patients partial response | #1 |
| conventional radiography workup | #1 |
| prednisone versus standard | #1 |
| received bortezomib | #1 |
| onj patients | #1 |
| patients plasmacytomas | #1 |
| mm009 010 | #1 |
| dexamethasone combination patients | #1 |
| maic mpt | #1 |
| subclonal fraction | #1 |
| prednisone control | #1 |
| stage adjuvant carboplatin | #1 |
| patients maintenance lenalidomide | #1 |
| pulsed cyclophosphamide | #1 |
| dexamethasone progressionfree survival | #1 |
| lendex patients | #1 |
| heterogeneity cochran | #1 |
| survival lenalidomide | #1 |
| activity thalidomide | #1 |
| bortezomib vmdt | #1 |
| symptomatic mm | #1 |
| patients diffuse pattern | #1 |
| versus mvac | #1 |
| maintenance mpr | #1 |
| development onj | #1 |
| arrow patients | #1 |
| diffuse mri pattern | #1 |
| mm003 | #1 |
| pad asct | #1 |
| diffuse mri | #1 |
| 62 months | #1 |
| vte myeloma patients | #1 |
| nongastric lymphomas | #1 |
| myeloma pet | #1 |
| egfr cysc | #1 |
| amyloidosis cardiac biomarkers | #1 |
| funding honoraria | #1 |
| zoledronic acid survival | #1 |
| ang2 angiogenin | #1 |
| mgus bones | #1 |
| increased levels dkk1 | #1 |
| mm patients sema4d | #1 |
| lenalidomide dose | #1 |
| patients deepening responses | #1 |
| endeavor arrow | #1 |
| vegfa angiogenin | #1 |
| treatment waldenstroms macroglobulinemia | #1 |
Key People For Multiple Myeloma
Meletios‐Athanassios Dimopoulos:Expert Impact
Concepts for whichMeletios‐Athanassios Dimopouloshas direct influence:Multiple myeloma, Breast cancer, Patients multiple myeloma, Renal impairment.
Meletios‐Athanassios Dimopoulos:KOL impact
Concepts related to the work of other authors for whichfor which Meletios‐Athanassios Dimopoulos has influence:Multiple myeloma, Breast cancer, Bone marrow, Stem cell, Zoledronic acid, Mm patients, Undetermined significance.
Tools
Is this your profile? Claim your profile Copy URL Embed Link to your profile |